Chemotherapy matched to tumor gene type for pancreatic cancer
Treatments studied
This study tailors standard chemotherapy for pancreatic cancer based on whether the tumor has a change in the SMAD4 gene. The goal is to see if a specific treatment plan works better for each gene type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic ductal adenocarcinoma.
- Your tumor has been tested for the SMAD4 gene (either changed/mutant or normal).
- Your cancer is considered resectable or borderline resectable (surgically removable).
- You have not had any prior treatment for this cancer.
- You are 18 years or older and in generally good health (able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tailoring chemotherapy drugs to your tumor's genetic signature helps treat borderline resectable pancreatic cancer (a type that sits between operable and inoperable). You'll receive chemotherapy before surgery, and the combination used will depend on specific markers found in your tumor.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This trial tests whether a special MRI scan can help doctors better plan treatment for people with pancreatic cancer that is borderline able to be removed by surgery. The study will check how the tumor responds to initial treatment before surgery.
This trial tests a three-drug chemotherapy combination (gemcitabine, cisplatin, and nab-paclitaxel) given before surgery for people with pancreatic cancer that can be removed or is on the edge of being removable. The goal is to shrink the tumor and improve surgery outcomes.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
This trial is testing a combination of three chemotherapy drugs (NALIRIFOX) given before surgery to shrink borderline resectable pancreatic cancer. The goal is to help make surgery more successful and improve outcomes.
Hear when a new Borderline Resectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.